<DOC>
	<DOCNO>NCT01407757</DOCNO>
	<brief_summary>RATIONALE : DNA analysis blood tissue sample may help doctor predict well patient respond treatment . It may also help doctor learn gemtuzumab ozogamicin work body . PURPOSE : This research study look gemtuzumab ozogamicin DNA sample patient acute myeloid leukemia treat COG-AAML0531 .</brief_summary>
	<brief_title>Study Gemtuzumab Ozogamicin Therapy DNA Samples From Patients With Acute Myeloid Leukemia Treated COG-AAML0531</brief_title>
	<detailed_description>OBJECTIVES : - To genotype genomic DNA acute myeloid leukemia ( AML ) patient treat COG-AAML0531 clinical trial CD33 ( PgP SOC3 ) single nucleotide polymorphism ( SNPs ) . OUTLINE : Archived DNA sample analyze single nucleotide polymorphism CD33 , PgP , SOC3 gene Sequenome platform . Results compare patient clinical outcome , include minimal-residual disease level post induction I ( chemotherapy gemtuzumab ozogamicin ) , complete remission rate , refractory disease various level bone marrow blast , development CNS/persistent disease , event-free survival , overall survival , toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed acute myeloid leukemia DNA sample patient treat COGAAML0531 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
</DOC>